There is a two week difference from completion of filled trial dates and they both share the same 28 day end point. Looks like leronlimab has a slight advantage but I have to say the management at relief is like an all star management and a who’s who of former big Pharma executives and former FDA employees. All in a penny stock company that has partners and tons of shares out. Like 3.25 Billion shares. Price won’t rise astronomical with that many shares but who really knows?

The all star management might be able to get more done with the golden handshake than CYDY’s management but I don’t want to underestimate Mr. Mahboob Rahman. He impresses me with his experience at former filings of BLA’s.

So I would say it’s a toss up for the first EUA between the two of them. Of coarse you know who I am rooting for...